Arkiv alla nyheter

3 mån måttlig LCHF vid T1DM RCT. Sv studie. The Lancet

Fördelar med måttlig lågkolhydratkost vid typ 1-diabetes hos vuxna

Måttlig lågkolhydratkost vid typ 1-diabetes hos vuxna har fördelar jämfört med traditionell kost. Medelnivån på blodsockret sänks och tiden per dygn med bra värden ökar, utan negativ hälsopåverkan. Det visar en studie vid Göteborgs universitet.Studien som publiceras i The Lancet Regional Health – Europe är den hittills största i sitt slag.

Deltagarna lottades att korsvis, under olika perioder, inta traditionell kost med 50 procent av energin från kolhydrater, eller måttlig lågkolhydratkost med 30 procent av energin från kolhydrater.

Det rör sig alltså om en måttfull minskning av kolhydrater, med dygnet-runtbevakning av samtliga deltagare via kontinuerlig blodsockermätning, så kallad CGM. Blodsockervärden registrerades var 15:e minut under de 16 studieveckorna, och följdes upp av dietist och diabetessjuksköterska.

Forskarna betonar att större förändringar av kolhydratintag vid typ 1-diabetes av säkerhetsskäl alltid bör ske i samråd med vården. Inte på egen hand, och särskilt inte vad gäller barn med typ 1-diabetes. Den nu aktuella studien gäller enbart vuxna.

Flera vinster med måttlig lågkolhydratkost

De 50 deltagarna hade alla typ 1-diabetes med förhöjt medelglukos, långtidsblodsocker, och injektionsbehandling med insulin eller insulinpump. Hälften var kvinnor, hälften män. Snittåldern låg på 48 år.

Båda kostvarianterna som prövades var hälsosamma gällande fett- och kolhydratkvalitet. De innehöll grönsaker, fiberrika kolhydratkällor, omättade fetter, nötter, frön och baljväxter, och var individanpassade av dietist.

Vid måttlig lågkolhydratkost visade sig deltagarna få mer tid inom det som kallas målområdet, alltså det spann inom vilket personer med typ 1-diabetes bör befinna sig vad gäller glukosvärde. Tidsökningen inom målområdet var i snitt 68 minuter per dygn jämfört med vid den traditionella kosten, samtidigt som tiden med förhöjda värden kapades med 85 minuter per dygn. Sammantaget värdefulla förändringar.

– Studien visar att en måttlig lågkolhydratkost sänker medelnivån av blodsockret och att fler patienter kan hålla blodsockret inom målområdet, vilket anses gynnsamt för att minska risken för organskador för personer med typ 1-diabetes, säger hon.

Studiens förstaförfattare är Sofia Sterner Isaksson, doktorand på Sahlgrenska akademin vid Göteborgs universitet och dietist i NU-sjukvården:

Inga negativa effekter av kosten

Forskarna såg inga tecken på negativa följder. Kolesterol- och blodtrycksnivåer låg på samma nivå för båda kosterna, och deltagarna upplevde sig dessutom något mer nöjda med den måttliga lågkolhydratkosten. Det har diskuterats om en form av syror, ketoner, kan bli för höga när kolhydrater minskas vid typ 1-diabetes, men dessa höll sig också på rimliga nivåer.

– Måttlig lågkolhydratkost kan vara ett bra behandlingsalternativ för vuxna med typ 1-diabetes med förhöjda glukosnivåer. Det är dock viktigt att kosten är hälsosam med särskilt fokus på fett- och kolhydratkvalitet, och att inte kolhydratmängden blir för låg, så att den inte längre kan anses säker. Vårdgivaren behöver därför erbjuda hjälp och uppföljning av kosten, säger Sofia Sterner Isaksson.

Ansvarig för studien är Marcus Lind, professor i diabetologi vid Göteborgs universitet och överläkare vid forskningsenheterna för diabetes på Sahlgrenska Universitetssjukhuset Östra och inom NU-sjukvården.

– Alla patienter behöver finna den kost som passar dem, i samråd med vården, men det har tidigare saknats tillräckligt stora studier där deltagarna lottats till olika experimentella behandlingar av det här slaget. Därför är det viktigt att vi kan presentera data som visar att måttlig lågkolhydratkost är effektiv och säker för vuxna med typ 1-diabetes, säger han.

Titel: The effect of carbohydrate intake on glycaemic control in individuals with type 1 diabetes: a randomised, open-label, crossover trial

Press release Göteborgs Universitet Sahlgrenska Akademin

______________________________________________________

• Läs hela artikeln som pdf free inkl abstract och författarnas ”Implications”,

4 v beh 30%, 4 v washout, 4 v ny beh 50%; RCT open label

Måttlig lågkolhydratkost som hälsosam medelhavskost; om den följs upp 6 mån eller längre

och om resultaten kvarstår, kan den utgöra underlag för framtida kliniska riktlinjer.

Studien tar upp kolhydrat-och fettkvalitet liksom dietistens arbete.

https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00218-1/fulltext

The effect of carbohydrate intake on glycaemic control in individuals with type 1 diabetes: a randomised, open-label, crossover trial

Summary

Background

Few studies have examined the effects of lower carbohydrate diets on glucose control in persons with type 1 diabetes (T1D). The objective of the study was to investigate whether a moderate carbohydrate diet improves glucose control in persons with T1D.

Methods

A randomised, multicentre, open-label, crossover trial over 12 weeks.

There were 69 individuals assessed for eligibility, 54 adults with T1D and HbA1c ≥ 58 mmol/mol (7.5%) were randomised.

Interventions were moderate carbohydrate diet versus traditional diet (30 vs 50% of total energy from carbohydrates) over four weeks, with a four-week wash-out period between treatments.

Masked continuous glucose monitoring was used to evaluate effects on glucose control. The primary endpoint was the difference in mean glucose levels between the last 14 days of each diet phase.

Findings

50 individuals were included in the full analysis set with a mean baseline HbA1c of 69 mmol/mol (8.4%), BMI 29 kg/m², age of 48 years, and 50% were female.

The difference in mean glucose levels between moderate carbohydrate and traditional diet was −0.6 mmol/L, 95% CI −0.9 to −0.3, p < 0.001. Time in range increased during moderate carbohydrate diet by 4.7% (68 min/24 h) (95% CI 1.3 to 8.0), p = 0.008. Time above range (>10 mmol/L) decreased by 5.9% (85 min/24 h), 95% CI −9.6 to −2.2, p = 0.003.

There were no significant differences in the standard deviation of glucose levels (95% CI −0.3 to 0.0 mmol/L, p = 0.15) or hypoglycaemia in the range <3.9 mmol/L (95% CI −0.4 to 2.9%, p = 0.13) and <3.0 mmol/L (95% CI −0.4 to 1.6%, p = 0.26).

Four participants withdrew, none because of adverse events. There were no serious adverse events including severe hypoglycaemia and ketoacidosis. Mean ketone levels were 0.17 (SD 0.14) mmol/L during traditional and 0.18 (SD 0.13) mmol/L during moderate carbohydrate diet (p = 0.02).

Interpretation

A moderate carbohydrate diet is associated with decreases in mean glucose levels and time above range and increases in time in range without increased risk of hypoglycaemia or ketoacidosis compared with a traditional diet in individuals with T1D.

• Evidence before this study

We searched PubMed with end date on May 15, 2017, using the search terms “carbohydrate restriction”, “low carbohydrate diet”, “LCD” and “type 1 diabetes” in combinations.

The titles and/or abstracts were screened and selected manually. Very few studies were found although the ones found were indicating positive effects on glucose control. Concerns about elevated risk of dyslipidaemia, hypoglycaemia and diabetic ketoacidosis also existed.

The studies found were either observational, small, not randomised, or lacked control groups. An update search in PubMed on May 15, 2023, using the same search terms did not reveal any new relevant evidence regarding glucose control or safety from larger randomised studies.

• Added value of this study

In this randomised, crossover trial over 12 weeks including 54 adults with type 1 diabetes the primary outcome mean glucose level was significantly reduced by −0.6 mmol/L (−11 mg/dL) with moderate restricted carbohydrate diet compared to traditional diet.

Other endpoints showed more time in range (3.9–10.0 mmol/L), time in tighter ranges (3.9–7.8 and 3.5–7.8 mmol/L), and less time with high and very high glucose levels as well as increased treatment satisfaction.

There was no increase in time in hypoglycaemia or cardiovascular risk factors such as lipids and blood pressure, no ketoacidosis, severe elevated ketone levels, or serious adverse events during the trial.

• Implications of all the available evidence

This study shows that a moderate carbohydrate diet is more effective than a traditional diet with a higher amount of carbohydrates in terms of decreasing mean glucose levels and time above range and increasing time in range and treatment satisfaction without increased risk of hypoglycaemia, dyslipidaemia, or ketoacidosis in individuals with type 1 diabetes.

These results show that a healthy moderate carbohydrate diet can be considered as a safe and effective treatment option for individuals with type 1 diabetes which extends possibilities for more differentiated diabetes care and provide further options to individualising diet treatment.

From the article Discussion

A moderate carbohydrate diet leads to significantly improved glucose control compared to a traditional diet with higher carbohydrate content in adults with T1D. The primary outcome, mean glucose level, was significantly reduced. Other endpoints showed more time in range, time in tighter ranges, and less time with high and very high glucose levels as well as increased treatment satisfaction. There was no increase in time in hypoglycaemia or cardiovascular risk factors such as lipids and blood pressure, no ketoacidosis, severe elevated ketone levels, or adverse events during the moderate carbohydrate diet.

The lack of diet studies in T1D may be due to need for them to be driven academically, little interest from the pharmaceutical industry, and their time-consuming nature. A few earlier studies showed improvements in glucose control with low carbohydrate diets in adults with T1D, but there have also been concerns about safety regarding the risk of elevated lipids and increased risk of ketoacidosis and hypoglycaemia.

Because evidence regarding efficacy and safety are lacking and the possible increased risk of ketoacidosis and severe hypoglycaemia, low carbohydrate diets are not yet recommended in dietary guidelines for people with T1D.

Earlier studies were either not randomised or very small. Low carbohydrate diets can differ widely in recommended carbohydrate amount, and most studies were of very low carbohydrate intake (less than 120 g and 5% of energy).

In this study our goal was to ensure a healthy diet to increase adherence for longer time periods. Safety was also a priority; therefore, we used a moderate carbohydrate diet with 30% of energy from carbohydrates compared to the traditional 50% which would make a clinically relevant difference in carbohydrate amount, but still likely be safe in both the short- and long-term. It also included healthy foods such as wholegrains, legumes, vegetables, and unsaturated fats according to guidelines to avoid negative health effects such as elevated blood pressure or dyslipidaemia.

The obtained effect on mean glucose corresponds to approximately 3 mmol/mol (0.3%) reduction in HbA1cwhich has been associated with a reduced risk of retinopathy.

Mean glucose level was chosen as the primary endpoint since the true glucose level without increased time in hypoglycaemia is a marker of both acute and long-term complications. Moreover, an increase in time in range of 5%, comparable to the current results of 4.7%, is considered a clinically relevant difference according to CGM guidelines.

Although participants increased in time in range the majority did not reach targets of 70 percent TIR indicating the need of additional improvements in diabetes care for many persons to achieve targets of glucose control. Further positive effects were seen in the decrease in time above range (>10 mmol/L) by 5.9% as well as the decrease in time above range (>13.9 mmol/L) of 3.6%. Since an exponential relationship exists between glucose levels and diabetes complications it is important to reduce time with very high glucose levels for all individuals with T1D.

One possible mechanism for the decrease in mean glucose level as well as the other positive effects on glucose control during the moderate carbohydrate diet may be due to fewer glucose excursions and peaks. Predicting the precise amount of insulin required becomes challenging due to several factors influencing insulin uptake such as physical activity during the day. Consequently, reducing the carbohydrate intake per meal potentially mitigates glycaemic peaks even if the insulin dosage is not entirely correct.

The current results indicate that a moderate carbohydrate diet should be included in dietary guidelines for persons with T1D as an alternative for decreasing mean glucose levels and that it can be considered safe, although it is important that it is possible for individuals to receive dietary advice from a dietitian to make sure the diet is healthy in terms of fat and carbohydrate sources.

Strengths of the study include randomised crossover design which reduces risk of confounding factors and person-to-person variation. It also included a detailed individual diet plan for each participant and during each diet phase with regular follow-up to increase adherence. Finally, it included a structured insulin management plan to keep it as comparable as possible between diet phases.

In this study participants measured ketone levels twice a week in the morning and evening, and they were asked to report adverse events during follow-up to determine risk of ketoacidosis and other possible negative effects of the diet. During moderate carbohydrate diet, ketone levels were slightly elevated, although levels overall were low and never were severely elevated. There were no cases of ketoacidosis, indicating that this level of carbohydrate intake may be safe. Insulin to body weight ratio was slightly decreased in the moderate carbohydrate diet, indicating that insulin doses were decreasing along with carbohydrate intake, which logically would be expected.

The total study period of 12 weeks and diet phases of 4 weeks each was intentional making it possible for participants to comply with dietary changes and all study procedures including keeping food diaries, measuring ketone levels, and using masked CGM to provide detailed glucose and diet data. This study mainly elucidates physiological effects and effects on glucose control of a moderate carbohydrate diet, and individual preferences likely exist which should be considered in clinical practice in order to increase compliance during longer treatment periods.

The food diaries indicated that differences in carbohydrate intake between the phases were less than planned, and a minority of participants lacked food records. Furthermore, carbohydrate intake was self-reported and thus may be biased.

Although food diaries were not registered in both phases by all participants the majority had recordings and the per protocol analyses using these data confirmed effects on glucose control for individuals differing in carbohydrate intake. Of note is that only adults with HbA1c of ≥58 mmol/mol (7.5%) were included in the study which may restrict results to this population.

Although the primary endpoint, mean glucose level, can be viewed as confirmatory, other glucometrics should be viewed as exploratory and preferentially confirmed in other studies. However, since there is a strong correlation between mean glucose level, time in range, and time in hyperglycaemia, our findings further support likely beneficial effect on other important glucometrics.

In summary, this study shows that in persons with T1D a moderate carbohydrate diet is more effective than a traditional diet with a higher amount of carbohydrates in terms of decreasing mean glucose levels and time above range and increasing time in range and treatment satisfaction without increased risk of hypoglycaemia, dyslipidaemia, or ketoacidosis.

These results show that a healthy moderate carbohydrate diet can be considered as a safe and effective treatment option for individuals with T1D which extends possibilities for more differentiated diabetes care and provides further options to individualising diet treatment.

https://www.thelancet.com/action/showPdf?pii=S2666-7762%2823%2900218-1

Nyhetsinfo

www red DiabetologNytt

Träffar: 0